A1M Pharma AB is a Sweden-based company, which is active within the healthcare sector. The Company conducts development and commercialization of treatment and diagnostics based on the alpha-1-microglobulin (A1M) protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic uses, such as alleviation of autoimmune diseases and stroke treatment. The Company works with the protein and conducts research at the Biomedical Center in Lund University, Sweden. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11/2024 - Q3 2024 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
13/09/24	29.60 kr	+2.07%	8,812
12/09/24	29.00 kr	0.00%	2,355
11/09/24	29.00 kr	0.00%	2,973
10/09/24	29.00 kr	+2.11%	5,753
09/09/24	28.40 kr	-1.39%	2,987

Delayed Quote Nasdaq Stockholm, September 13, 2024 at 05:00 pm

More quotes

Income Statement and Estimates

More financial data

Profit revisions

Estimate revisions

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 13/09/2024 BST			5-day change	1st Jan Change
29.60 ^SEK	+2.07%		+2.78%	-17.32%

08-29	First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER	CI
08-27	Guard Therapeutics Plans New SEK80 Million Rights Issue to Fund Kidney Drug Study	MT

Capitalization	357M 34.91M 2.66B	P/E ratio 2024 *	-5.06x	P/E ratio 2025 *	-4.78x
Enterprise value	276M 27.04M 2.06B	EV / Sales 2024 *	-	EV / Sales 2025 *	-
Free-Float	91.08%	Yield 2024 *	-	Yield 2025 *	-

First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER	08-29	CI
Guard Therapeutics Plans New SEK80 Million Rights Issue to Fund Kidney Drug Study	08-27	MT
Guard Therapeutics International AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-22	CI
Guard Therapeutics Receives Regulatory EU Approvals to Include Patients in its Phase 2b Study POInter	08-08	CI
Guard Therapeutics Announces Scientific Journal American Journal of Physiology ? Renal Physiology Publishes Article Summarizing Important Preclinical Results of Its Clinical Drug Candidate RMC-035	05-27	CI
Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Guard Therapeutics International AB announced that it expects to receive SEK 59.99074 million in funding from Swedbank Robur Fonder AB, Industrifonden, Strand Kapitalforvaltning AB and another investor	05-07	CI
Guard Therapeutics Receives First Regulatory Approval for the Phase 2b Study POINTER	04-15	CI
Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-21	CI
Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-21	CI
Guard Therapeutics Presents Development Strategy and New Preclinical Results at R&D Update	01-31	CI
US FDA Gives Positive Feedback on Guard Therapeutics’ RMC-035 Development Plan; Stock Plunges	01-15	MT
Guard Therapeutics International AB Announces Fda Provides Positive Feedback to Guard Therapeutics Regarding the Continued Development Plan for RMC-035	01-15	CI

Guard Therapeutics publishes prospectus due to upcoming rights issue	09-02	AQ
First patient dosed in Guard Therapeutics’ phase 2b study POINTER	08-29	AQ
Guard Therapeutics carries out announced rights issue (repair issue)	08-27	AQ
Guard Therapeutics receives regulatory EU approvals to include patients in its Phase 2b study POINTER	08-08	AQ
Guard Therapeutics carries out a directed share issue of approximately SEK 60 million and intends to carry out a repair issue	06-17	AQ

Guard Therapeutics International AB Share Price

Equities

GUARD

SE0021181559

Biotechnology & Medical Research

Valuation: Guard Therapeutics International AB

Chart: Guard Therapeutics International AB

Latest news: Guard Therapeutics International AB

Press Releases: Guard Therapeutics International AB

News in other languages: Guard Therapeutics International AB

Quotes and Performance

Course Extremes

Managers and Directors: Guard Therapeutics International AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

ERS Test AG: Vorabbekanntmachung über die Veröffentlichung von Zahlungsberichten gemäß § 116 WpHG	07/04/21
DGAP-AFR : ERS Test AG: Vorabbekanntmachung über die Veröffentlichung von Zahlungsberichten gemäß § 116 WpHG	07/04/21
ERS Test AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG	07/04/21
DGAP-AFR : ERS Test AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG	07/04/21

1 day	+2.07%
1 week	+2.78%
Current month	+1.37%
1 month	+3.50%
3 months	-21.28%
6 months	+56.61%
Current year	-17.32%

Director	Title	Age	Since
Tobias Larsson Agervald CEO	Chief Executive Officer	48	30/11/18
Karin Botha DFI	Director of Finance/CFO	51	13/09/20
Michael Reusch CTO	Chief Tech/Sci/R&D Officer	64	31/12/21

Manager	Title	Age	Since
Göran Forsberg BRD	Director/Board Member	61	28/05/19
Johannes Hulthe BRD	Director/Board Member	54	28/05/19
Johan Bygge CHM	Chairman	68	30/04/21

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
GUARD THERAPEUTICS INTERNATIONAL AB	+2.07%	+2.78%	+289.47%	-67.65%	34.96M
LONZA GROUP AG	+2.25%	+3.47%	+13.39%	-28.56%	47.27B
IQVIA HOLDINGS INC.	+0.13%	-1.80%	+12.09%	-7.32%	43.52B
ALNYLAM PHARMACEUTICALS, INC.	+1.35%	+7.49%	+37.40%	+41.12%	34.06B
CELLTRION, INC.	-0.20%	+2.09%	+32.25%	-21.27%	30.33B
MODERNA, INC.	-2.01%	-6.32%	-39.47%	-84.04%	26.25B
ICON PUBLIC LIMITED COMPANY	+0.10%	-0.83%	+14.60%	+13.07%	24.84B
UNITED THERAPEUTICS CORPORATION	-0.58%	-1.88%	+54.50%	+62.67%	15.09B
BIO-TECHNE CORPORATION	+2.01%	+4.45%	+0.85%	-41.42%	11.85B
MEDPACE HOLDINGS, INC.	+1.95%	+4.74%	+25.58%	+94.22%	10.88B
Average	+0.71%	+1.37%	+44.07%	-3.92%	24.41B
Weighted average by Cap.	+0.57%	+1.14%	+15.81%	-5.39%

	2024 *	2025 *
Net sales	-	-
Net income	-86M -8.41M -641M	-91M -8.9M -678M
Net Debt	-108M -10.56M -805M	-17M -1.66M -127M